

## CASE REPORT

# A Case of Cutaneous Extramedullary Hematopoiesis Associated with Idiopathic Myelofibrosis

F. Corella,<sup>a</sup> M. A. Barnadas,<sup>a</sup> R. Bordes,<sup>b</sup> R. Curell,<sup>b</sup> I. Espinosa,<sup>b</sup> C. Vergara,<sup>b</sup> and A. Alomar<sup>a</sup>

<sup>a</sup>Servicio de Dermatología and <sup>b</sup>Servicio de Anatomía Patológica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

**Abstract.** Cutaneous extramedullary hematopoiesis is a rare manifestation of chronic myeloproliferative processes, mainly chronic idiopathic myelofibrosis. In adults, it manifests as macules, papules, nodules, and ulcers on the trunk. The lesions usually appear soon after diagnosis and the possibility of a relationship between splenectomy and the appearance of extramedullary foci of hematopoiesis is still debated. Diagnosis is based on histopathology showing an infiltrate with different combinations of myeloid and erythroid cell precursors and megakaryocytes. Symptomatic treatment is provided alongside treatment of the underlying disease. We report a new case associated with chronic idiopathic myelofibrosis in which foci of cutaneous extramedullary hematopoiesis were observed 9 years after initial diagnosis. The lesions were progressive and the patient went on to develop acute myeloid leukemia.

**Key words:** extramedullary hematopoiesis, idiopathic myelofibrosis, erythroid precursors, myeloid precursors, megakaryocytes.

## HEMATOPOYESIS EXTRAMEDULAR CUTÁNEA EN MIELOFIBROSIS IDIOPÁTICA: A PROPÓSITO DE UN CASO

**Resumen.** La hematopoyesis extramedular cutánea es una manifestación infrecuente de los procesos mieloproliferativos crónicos, principalmente de la mielofibrosis crónica idiopática. En el adulto se manifiesta como máculas, pápulas, nódulos y úlceras en el tronco. La aparición suele darse poco después del diagnóstico y todavía es una cuestión debatida la posible relación entre la esplenectomía y la aparición de los focos de hematopoyesis extramedular. El diagnóstico se realiza mediante estudio histopatológico y la visualización de un infiltrado compuesto por diferentes combinaciones de precursores mieloides, eritroides y células megacariocíticas. El tratamiento es sintomático y el propio de la enfermedad de base. Aportamos un nuevo caso asociado a mielofibrosis crónica idiopática que a los 9 años del diagnóstico presentó focos de hematopoyesis extramedular cutánea. Dichas lesiones siguieron un curso progresivo, desarrollando posteriormente una leucemia mieloide aguda.

**Palabras clave:** hematopoyesis extramedular, mielofibrosis idiopática, precursores eritroides, mieloides y megacariocitos.

## Introduction

Cutaneous extramedullary hematopoiesis is defined as the presence of hematopoietic elements outside the bone marrow. The process occurs physiologically in embryos from 8 to 45 cm,<sup>1</sup> and subsequent manifestations are rare.

Cases have been described in newborns in the context of intrauterine infections and hematologic disorders.<sup>2</sup> In adults, it can be associated with myelodysplastic and myeloproliferative syndromes, namely, disorders with ineffective or excessive hematopoiesis due to the formation of a neoplastic clone derived from an abnormal hematopoietic stem cell.<sup>3</sup> The processes most commonly associated with cutaneous extramedullary hematopoiesis are chronic myeloproliferative syndromes, in particular idiopathic myelofibrosis. It has been anecdotally associated with other entities, such as pachydermoperiostosis, pilomatixoma, hemangioma, and even after administration of interleukin 3 by subcutaneous injection.<sup>3</sup> We describe the case of a patient with a history of idiopathic


Correspondence:  
Francisca Corella  
Departamento de Dermatología  
Hospital Santa Creu i Sant Pau  
Sant Antoni Maria Claret, 167  
08025 Barcelona, Spain  
fcorella@santpau.es



**Figure 1.** Indurated erythematous-violaceous nodules on the left breast.



**Figure 2.** Indurated erythematous-violaceous nodules on the scalp.



**Figure 3.** Infiltrate composed of myeloid precursors and megakaryocytes. Hematoxylin-eosin,  $\times 200$ .

myelofibrosis who, after 9 years, developed cutaneous lesions with histologic findings consistent with foci of cutaneous extramedullary hematopoiesis.

## Case Description

A 55-year-old woman consulted in November 2005 for 2 nodules, one that had appeared in November 2004 in the upper left mammary region and another in October 2005 in the lower mammary region. She also reported 3 nodules present on the scalp since 2002 for which she had not consulted earlier.

Relevant history included the diagnosis of essential thrombocytosis in 1984 with subsequent transformation to idiopathic myelofibrosis in 1993. The patient remained asymptomatic until 1998, when she developed progressive splenomegaly, requiring therapeutic splenectomy in 2001 and the initiation of hydroxyurea therapy, followed by anagrelide. Both drugs had been discontinued due to adverse effects, although the patient continued with symptomatic treatment with regular follow-up. Due to disease progression, a bone marrow biopsy was performed in February 2004 and showed conversion of idiopathic myelofibrosis to acute myeloid leukemia. As a result, treatment with 6-mercaptopurine was initiated.

The examination revealed 2 indurated erythematous-violaceous nodules of  $15 \times 15$  mm (upper nodule) and  $10 \times 8$  mm (lower nodule) in the left mammary region (Figure 1). Three additional nodules of similar characteristics (10 mm, 20 mm, and 30 mm) were also observed on the scalp (Figure 2).

Histologic study of a biopsy taken from a breast lesion and another from the scalp showed a dense infiltrate in the reticular dermis composed of myeloid cells (at different stages of maturation) and megakaryocytes. Immunohistochemistry was positive for myeloperoxidase and CD68, with an insignificant number of CD34<sup>+</sup> cells. These findings were consistent with our finding of cutaneous extramedullary hematopoiesis (Figures 3, 4, and 5).

A recent laboratory workup showed hemoglobin 90 g/L, platelets  $165 \times 10^9$ /L, and leukocytes  $8.48 \times 10^9$ /L (5% blasts, 57% neutrophils, 16% lymphocytes, 1% eosinophils and basophils, 12% leukoblasts, 2% myelocytes, and 2% metamyelocytes).

Due to slow progression of the lesions and the lack of other symptoms, a wait-and-see approach was taken. The lesions had remained stable at the time of writing.

## Discussion

Idiopathic myelofibrosis is characterized by the proliferation of endothelial cells and fibroblasts in the bone marrow,<sup>4</sup> resulting in disruption of the barrier between the bone marrow and peripheral blood, with subsequent migration and proliferation of hematopoietic stem cells in other organs.<sup>3</sup>


Extramedullary hematopoiesis in the context of idiopathic myelofibrosis was first described by Hickling in 1937 and

cited by Kuo et al.<sup>5</sup> In most reported cases, the foci of extramedullary hematopoiesis are the spleen and liver. Other sites include the lymph nodes, retroperitoneum, spine, kidneys, adrenal glands, gastrointestinal tract, lung, and breasts. Skin involvement is rare, and other organs such as the testicles are not usually affected.<sup>6</sup> The fact that some organs are affected more often than others may result from the predilection of hematopoietic stem cells for implanting into organs already predisposed to hematopoiesis, such as the spleen or liver. A recent review of 510 patients with extramedullary hematopoiesis found that the hematopoietic foci were nonhepatosplenic in only 27 of these patients and that 18 of the 27 cases were secondary to underlying chronic idiopathic myelofibrosis.<sup>7</sup>


Skin involvement is uncommon and has an estimated prevalence of 0.4% of cases.<sup>8</sup> Splenectomy is believed to act as a predisposing factor for seeding of extramedullary foci of hematopoiesis in the skin through contamination during the surgical procedure<sup>8,9</sup> or expansion of these hematopoiesis foci from the spleen to other organs, such as the liver or skin.<sup>10</sup> The relationship between splenectomy and hematopoiesis in the skin is still under debate; although several cases have been described, most had no history of prior splenectomy<sup>1-3,6,11</sup> or an excessively long time between splenectomy and onset of hematopoiesis in the skin.<sup>12,13</sup> The cutaneous lesions can manifest in a variety of ways: as macules, papules, nodules, and even ulcers.<sup>5</sup> Several cases have been described of angioma-like cutaneous lesions<sup>14</sup> and others with blisters and bleeding.<sup>10</sup> The most common site is the thorax and abdomen in adults and the head and neck in children.<sup>2</sup> In most cases, there are usually more than 10 lesions,<sup>9,11-13,15</sup> although isolated cases of more than 50 lesions have been reported.<sup>1</sup> The diameter is usually between 0.5 cm and 5 cm,<sup>9,10,12-13</sup> but may be larger than 10 cm.<sup>8</sup> No relationship has been found between the degree of fibrosis in bone marrow and the extent of cutaneous extramedullary hematopoiesis lesions.<sup>15</sup>

In most cases, the lesions tend to appear within a year after diagnosis of myelofibrosis, although an occasional case has been published of skin lesions appearing up to 8 years later<sup>14</sup> or in which onset of the disease coincided with the appearance of cutaneous lesions.<sup>10,16</sup>

Histologically, the lesions are characterized by a polymorphous dermal infiltrate, composed of a combination of myeloid, erythroid, and megakaryocyte precursors.<sup>13</sup> A review of case reports from patients with cutaneous extramedullary hematopoiesis by Mizoguchi et al<sup>10</sup> found that a high number of cases had precursors of only 1 or 2 hematopoietic series. In children, erythroid precursors are usually predominant and megakaryocytes tend to be absent, whereas in adults, megakaryocytes are usually predominant and only half the cases with cutaneous extramedullary hematopoiesis in adults show erythroid precursors in the biopsy.<sup>2</sup> Positive reactions have been observed for



**Figure 4.** Detailed view of a megakaryocyte (black arrow). Hematoxylin-eosin,  $\times 400$ .



**Figure 5.** Detailed view of the myeloid precursors (red arrow) and eosinophils (black arrow). Hematoxylin-eosin,  $\times 400$ .

myeloperoxidase (myeloid series) and von Willebrand factor (megakaryocytic series) in immunohistochemical studies. Most myeloid precursor cells were only positive for myeloperoxidase, confirming their granulocytic origin. Only a few cells were positive for CD68, which is expressed in both mature and immature granulocytes and in monocytes and macrophages.<sup>16</sup> In a case study published by Kwon et al,<sup>11</sup> a high number of eosinophil precursors were observed; however, the significance of this is not yet clear.

The main differential diagnosis should be performed with leukemia cutis because idiopathic chronic myelofibrosis has progressed to acute myeloid leukemia in 8% of cases.<sup>9,17</sup> In the case we describe, established acute myeloid leukemia was present when the biopsies were taken. The cutaneous infiltrate may actually not be leukemic infiltration. The long history of the lesions and the histologic characteristics of the infiltrate do not support this diagnosis, as a leukemic

infiltrate would be expected to show greater monomorphism and cell density, as well as a higher number of CD34<sup>+</sup> cells.

Death caused by leukemic transformation of the disease has been reported,<sup>15</sup> particularly when atypical megakaryocytes are present.<sup>5</sup>

Treatment of cutaneous extramedullary hematopoiesis is recommended if the cutaneous lesions are symptomatic or if necessary because of the site or extent, or if the underlying disease requires systemic treatment. In some published reports, the cutaneous lesions responded to treatment of the underlying disease with hydroxyurea<sup>8,15</sup> or interferon alfa,<sup>16</sup> although therapeutic failures have also occurred in both approaches.<sup>13</sup> Several published case studies have described cutaneous lesions treated by electron beam with good response.<sup>5,8</sup>

Noteworthy in the case we have described is the appearance of foci of cutaneous extramedullary hematopoiesis 9 years after the diagnosis of idiopathic myelofibrosis and the development of new foci after leukemic transformation of the disease.

#### Conflicts of Interest

The authors declare no conflicts of interest.

## References

1. Puig L, Pilar García M, de Moragas JM, Matias Guiu X, Moreno A, Cadafalch J. Cutaneous extramedullary hematopoiesis in a patient with acute myelofibrosis. *Arch Dermatol*. 1988;124:329-31.
2. Fernández Acenero MJ, Borbujo J, Villanueva C, Peñalver J. Extramedullary hematopoiesis in an adult. *J Am Acad Dermatol*. 2003;48:S62-3.
3. Haniffa MA, Wilkins BS, Blasdale C, Simpson NB. Cutaneous extramedullary hematopoiesis in chronic myeloproliferative and myelodysplastic disorders. *J Am Acad Dermatol*. 2006;55:S28-31.
4. Wolf BC, Neiman RS. Myelofibrosis with myeloid metaplasia: pathophysiologic implications of the correlation between bone marrow changes and progression of splenomegaly. *Blood*. 1985;65:803-9.
5. Kuo T. Cutaneous extramedullary hematopoiesis presenting as leg ulcers. *J Am Acad Dermatol*. 1981;4:592-6.
6. Ruberto E, Espinola R, Brusco J, Bacchiocchi M, Zoppi J, Paz R. [Idiopathic myelofibrosis with extramedullary hematopoiesis foci in the skin and testicles. Report of a case]. *Sangre (Barc)*. 1995;40:157-60.
7. Koch CA, Li CY, Mesa RA, Tefferi A. Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment. *Mayo Clin Proc*. 2003;78:1223-33.
8. Hocking WG, Lazar GS, Lipsett JA, Busuttill RW. Cutaneous extramedullary hematopoiesis following splenectomy for idiopathic myelofibrosis. *Am J Med*. 1984;76:956-8.
9. Revenga F, Horndler C, Aguilar C, Paricio J. Cutaneous extramedullary hematopoiesis. *Int J Dermatol*. 2000;39:957-8.
10. Mizoguchi M, Kawa Y, Minami T, Nakayama H, Mizoguchi H. Cutaneous extramedullary hematopoiesis in myelofibrosis. *J Am Acad Dermatol*. 1990;22:351-5.
11. Kwon KS, Lee JB, Jang HS, Chung TA, Oh CK. A case of cutaneous extramedullary hematopoiesis in myelofibrosis with a preponderance of eosinophilic precursor cells. *J Dermatol*. 1999;26:379-84.
12. Patel BM, Su WP, Perniciero C, Gertz MA. Cutaneous extramedullary hematopoiesis. *J Am Acad Dermatol*. 1995;32:805-7.
13. Hoss DM, McNutt NS. Cutaneous myelofibrosis. *J Cutan Pathol*. 1992;19:221-5.
14. Pagerols X, Curc N, Marti JM, Vives P. Cutaneous extramedullary haematopoiesis associated with blast crisis in myelofibrosis. *Clin Exp Dermatol*. 1998;23:296-7.
15. Schofield JK, Shun JL, Cerio R, Grice K. Cutaneous extramedullary hematopoiesis with a preponderance of atypical megakaryocytes in myelofibrosis. *J Am Acad Dermatol*. 1990;22:334-7.
16. Lane JE, Walker AN, Kulharya A, Marzec T. Cutaneous sclerosing extramedullary hematopoietic tumor in chronic myelogenous leukemia. *J Cutan Pathol*. 2002;29:608-12.
17. Ribera JM, Bladé J, Feliu E, Palo J, Mascaró JM, Rozman C. [Idiopathic myelofibrosis with cutaneous myeloid metaplasia]. *Sangre (Barc)*. 1984;29:478-80.